Stocks Health care CLYM
NASDAQ · Health careClimb Bio, Inc. (CLYM)
It posted a net loss of $59.3M. In fiscal 2025 capital spending exceeded operating cash flow by $54.5M. At September 30, 2026 it held $39.7M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 5, 2026.
Key facts about Climb Bio, Inc.
- Net worth
- Climb Bio, Inc. has a market value (market cap) of $632.4M at the latest share price, and shareholders' equity of $228.1M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $54.4M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 5, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Climb Bio, Inc.'s next report is expected around March 4, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Climb Bio, Inc. does
Climb Bio, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker CLYM.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$59.9M | -$0.88 | -$54.5M |
| 2024 | n/a | -$73.9M | -$1.53 | -$15.6M |
| 2023 | n/a | -$35.1M | -$1.30 | -$20.6M |
| 2022 | n/a | -$45.2M | -$1.72 | n/a |
| 2021 | n/a | -$47.5M | -$4.24 | n/a |
| 2021 | n/a | -$20.7M | -$10.49 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Climb Bio, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 9, 2026Activist stake changed SCHEDULE 13D/A
- November 5, 2026Passive stake changed SCHEDULE 13G/A
- November 5, 2026
- November 5, 2026
- November 5, 2026
- October 28, 2026Passive stake (5% or more) SCHEDULE 13G
- October 27, 2026Passive stake (5% or more) SCHEDULE 13G
- October 26, 2026
- October 23, 2026
- September 3, 2026
Insider trades
What the people running Climb Bio, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $1.4M worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 28, 2026 | Ra Capital Management, L.P.Director, 10% owner | Exercised optionsindirect | 10,000 | $34.6K |
| September 28, 2026 | Ra Capital Management, L.P.Director, 10% owner | Exercised optionsindirect | 10,000 | $30K |
| September 28, 2026 | Ra Capital Management, L.P.Director, 10% owner | Exercised optionsindirect | 10,000 | $78.9K |
| September 28, 2026 | Ra Capital Management, L.P.Director, 10% owner | Exercised optionsindirect | 40,000 | $51.6K |
| September 15, 2026 | Thomas Stephen BasilDirector | Soldpre-planned (10b5-1) | 100,000 | $1.4M |
| June 29, 2026 | Brennan AoifePresident and CEO, Director | Soldpre-planned (10b5-1) | 30,902 | $407K |
| June 27, 2026 | Brennan AoifePresident and CEO, Director | Exercised options | 68,750 | - |
| February 26, 2026 | Thomas Stephen BasilDirector | Soldpre-planned (10b5-1) | 16,313 | $114.3K |
Who owns CLYM
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| RA Capital Management, L.P.13D, may seek influence with 4 related filers | 33% | July 7, 2026 |
| Fmr LLC13G, passive with 1 related filers | 11.9% | July 8, 2026 |
| Pontifax VI G.P. L.P.13G, passive with 3 related filers | 7.7% | September 18, 2025 |
| Deerfield Mgmt, L.P.13G, passive with 3 related filers | 5.25% | October 28, 2026 |
| BlackRock, Inc.13G, passive | 5% | October 27, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 109 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| RA Capital Management, L.P. | 11,300,939 | 0 |
| Fmr LLC | 6,790,364 | +6,783,967 |
| UBS Group AG | 3,404,866 | +3,318,921 |
| Braidwell LP | 2,797,375 | +1,267,700 |
| Adage Capital Partners GP, L.L.C. | 2,506,000 | new |
| BlackRock, Inc. | 2,354,872 | +1,953,223 |
| Cormorant Asset Management, LP | 2,106,000 | new |
| Frontier Capital Management Co LLC | 1,939,019 | new |
| Vanguard Capital Management LLC | 1,698,654 | +519,995 |
| Woodline Partners LP | 1,582,291 | new |
| Citadel Advisors LLC | 1,297,972 | +952,309 |
| Redmile Group, LLC | 1,226,330 | new |
| Great Point Partners LLC | 1,000,000 | -334,130 |
| Affinity Asset Advisors, LLC | 972,000 | +272,000 |
| Millennium Management LLC | 908,198 | -368,062 |
| ADAR1 Capital Management, LLC | 822,649 | +224,987 |
| Driehaus Capital Management LLC | 790,000 | +189,054 |
| Geode Capital Management, LLC | 782,199 | +469,200 |
| Stempoint Capital LP | 742,745 | new |
| State Street Corp | 686,772 | +554,772 |
Insiders
3 insiders reported holding 625,700 shares in total, about $6.9M at the last price.
| Holder | Shares |
|---|---|
| Thomas Stephen BasilDirector | 467,969 |
| Brennan AoifePresident and CEO, Director | 87,731 |
| Ra Capital Management, L.P.Director, 10% owner | 70,00070,000 held indirectly |
Questions about CLYM
What does Climb Bio, Inc. do?
Climb Bio, Inc. is a company in the Health care sector, listed on NASDAQ as CLYM. Its shares trade on NASDAQ under the ticker CLYM.
What is Climb Bio, Inc.'s net worth?
Climb Bio, Inc. has a market value (market cap) of $632.4M at the latest share price, and shareholders' equity of $228.1M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Climb Bio, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $59.3M.
When did Climb Bio, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 5, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the activist stake changed from November 9, 2026.
When is Climb Bio, Inc.'s next earnings report?
Climb Bio, Inc.'s next report is expected around March 4, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare CLYM with
Follow CLYM
Get an email when Climb Bio, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Climb Bio, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.